**Specifications Table**TableSubject area*Medicine*More specific subject area*Cardiology*Type of data*Tables*How data was acquired*Echocardiography, biochemical testing of serum BNP and creatinine*Data format*Analysed*Experimental factors*Consecutive patients with chronic heart failure with reduced ejection fraction (EF)*Experimental features*Retrospective, multicentre, observational study*Data source location*Pisa, Perugia, Pavia; Verona, Auckland, Veruno*Data accessibility*Data is with this article*

**Value of the data**•Echo and BNP guided HF care can provide a tailored approach to the diuretic treatment [@bib1].•This strategy can prevent worsening renal function in chronic HF and, thus, may impact patients' survival [@bib2], [@bib3].

1. Data {#s0005}
=======

Transthoracic two-dimensional and Doppler echocardiographic examination was carried out with commercial equipments with 2nd-harmonic imaging. BNP concentrations were processed by Alere Triage BNP Test for Beckman Coulter Immunoassay Systems (Alere San Diego Inc., San Diego, CA, USA), a two-site immunoenzymatic (sandwich) quantitative assay. The eGFR was calculated from the simplified formula derived from the Modification of Diet in Renal Disease study. [Supplementary Table 1](#s0020){ref-type="sec"} shows the characteristics of the study groups. [Supplementary Table 2](#s0015){ref-type="fn"} describes the data on diuretic use (furosemide dose) and the changes in renal function [@bib1].

2. Experimental design, materials and methods {#s0010}
=============================================

This was a retrospective, multicenter, observational study that involved 1137 consecutive outpatients (total cohort). In a group of 570 patients with HF (mean ejection fraction \[EF\]=30%), management was guided according to the presence of echo signs of elevated left ventricular filling pressure and serum BNP levels, while in the other (*n*=567, mean EF=33%), management was based on clinical judgment. In the latter group, echocardiography was repeated only in the case of changes in clinical status.

Transparency document. Supplementary material {#s0020}
=============================================

Supplementary material.

Appendix A. Supplementary material {#s0030}
==================================

Supplementary material.

Transparency data associated with this article can be found in the online version at <http://dx.doi.org/10.1016/j.dib.2016.11.009>.

Supplementary data associated with this article can be found in the online version at <http://dx.doi.org/10.1016/j.dib.2016.11.009>.

[^1]: On behalf of the investigators of the Network Labs Ultrasound (NEBULA) in Heart Failure Study Group
